Charles Schwab Investment Management Inc Point Biopharma Global Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$6.67 - $9.71 $2.98 Million - $4.34 Million	446,910 Added 184.47%	689,179 $4.6 Million
Q2 2023 Aug 09, 2023	BUY	$6.86 - $10.86 $69,944 - $110,728	10,196 Added 4.39%	242,269 $2.19 Million
Q1 2023 May 11, 2023	BUY	$6.78 - $8.1 $78,437 - $93,708	11,569 Added 5.25%	232,073 $1.69 Million
Q4 2022 Feb 13, 2023	BUY	$5.72 - $9.78 $161,727 - $276,519	28,274 Added 14.71%	220,504 $1.61 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $3,192 - $4,546	441 Added 0.23%	192,230 $1.49 Million
Q2 2022 Aug 15, 2022	BUY	$5.6 - $9.5 $911,181 - $1.55 Million	162,711 Added 559.57%	191,789 $1.31 Million
Q3 2021 Nov 16, 2021	BUY	$7.42 - $11.26 $215,758 - $327,418	29,078 New	29,078 $224,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.